Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
BioPharma Dive
On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
pharminent
April 23, 2026 (Last updated: April 24, 2026)
BioPharma Dive
On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
